Helicobacter pylori seropositivity, the interleukin 1B polymorphism, and smoking among first-visit outpatients

Asian Pacific Journal of Cancer Prevention

Volumn 3, Issue 1, 2012, Pages 23-28

  Hamajima, Nobuyuki ^a   Ito, Hidemi ^a,b   Matsuo, Keitaro ^a,c   Tajima, Kazuo ^a   Tominaga, Suketami ^d  

^a Division of Epidemiology and Prevention   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Helicobacter pylori; IL 1B C 31T; PCR CTPP; Smoking

Indexed keywords

EID: 0038047244     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Asaka M, Takeda H, Sugiyama T, Kato M (1997). What role does Helicobacter pylori play in gastric cancer? Gastroenterology, 113, S56-S60.
2. Bardhan PK (1997). Epidemiological features of Helicobacter pylori infection in developing countries. Clin Infect Dis, 25, 973-8.
3. Beales IL, Calam J (1998). Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut, 42, 227-34.
4. Bertoni G, Sassatelli R, Nigrisoli E, et al (1996). Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol, 91, 258-63.
5. Blaser MJ, Berg DE (2001). Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest, 107, 767-73.
6. Brown, LM (2000). Helicobacter pylori: Epidemiology and routes of transmission. Epidemiol Rev, 22, 283-97. Cutler AF, Schubert TT (1993). Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol, 88, 505-9.
7. Cutler AF, Schubert TT (1993). Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol, 88, 505-9.
8. Dianarello CA (1996). Biologic basis for interleukin-1 in disease. Blood, 87, 2095-147.
9. El-Omar EM, Carrington M, Chow W-H, et al (2000). Interleukin- 1 polymorphisms associated with increased risk of gastric cancer. Nature, 404, 398-402. Corrections 2001;412:99.
10. El-Omar EM (2001). The importance of interleukin 1β in Helicobacter pylori associated disease. Gut, 48, 743-7.
11. The EUROGAST Study Group (1993). Epidemiology of, and risk factors for Helicobacter pylori infection among 2194 asymptomatic subjects in 17 populations. Gut, 34, 1672-6.
12. Evans DJ, Evans DG, Graham DY, Klein PD (1989). A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology, 96, 1004-8.
13. Fontham ETH, Ruiz B, Perez A, Hunter F, Correa P (1995). Determinations of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol, 90, 1094-101.
14. Go MF (1997). What are the host factors that place an individual at risk for Helicobacter pylori - associated disease? Gastroenterology, 113, S15-S20.
15. Goddard AF, Spiller RC (1996). Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther, 10, 1009-13.
16. Hamajima N, Inoue M, Tajima K, et al (1997). Lifestyle and anti- Helicobacter pylori immunoglobulin G antibody among outpatients. Jpn J Cancer Res, 88, 1038-43.
17. Hamajima N, Saito T, Matsuo K, et al (2000). Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res, 91, 865-8.
18. Hamajima N, Matsuo K, Saito T, et al (2001a). Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection. Jpn J Cancer Res, 92, 383-9.
19. Hamajima N, Matsuo K, Suzuki T, et al (2001b). Low expression myeloperoxidase genotype negatively associated with Helicobacter pylori infection. Jpn J Cancer Res, 92, 488-93.
20. Hamajima N, Matsuo K, Saito T, et al (2001c). Gene-environment interactions and polymorphism studies for cancer risks in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pacific J Cancer Prev, 2, 99-107.
21. Hulkkonen J, Laippala P, Hurme M (2000). A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1β plasma levels in healthy individuals. Eur Cytokine Netw, 11, 251-5.
22. Ikehara Y, Nishihara S, Yasutomi H, et al (2001). Polymorphisms of two fucosyltransferase genes (Lewis and secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobaster pylori IgG antibody. Cancer Epidemiol Biomarkers Prev, 10, 971-7.
23. Jung H, Kim JM, Song IS, Kim CY (1997). Helicobacter pylori induces an array of pro-inflammatory cytokines in humangastric epithelial cells: quantification of mRNA for interleukin- 8, -1 alpha/beta, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and tumor necrosis factor-alpha. J Gastroenterol Hepatol, 12, 473-80.
24. Kamada T, Haruma K, Komoto K, et al (1999). Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter, 4, 204-10
25. Katsuda N, Hamajima N, Matsuo K, et al (2001). Association between the interleukin 1B (C-31T) polymorphism and Helicobacter pylori infection in health checkup examinees. Jpn J Public Health, 48, 604-12.
26. Kuschner WG, D'Alessandro A, Wong H, Blanc PD (1996). Dosedependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J, 9, 1989-94.
27. Labenz J, Stolte M, Blum AL, et al (1995). Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut, 37, 39-43.
28. Machado JC, Pharoah P, Sousa S, et al (2001). Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology, 121, 823-9.
29. Maconi G, Parente F, Russo A, et al (2001). Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol, 96, 359-66.
30. Malaty HM, Engstrand L, Pedersen NL, Graham DY (1994). Helicobacter pylori infection: genetic and environmental influence. A study of twins. Ann Intern Med, 129, 982-6.
31. Matsuo K, Hamajima N, Tominaga S, et al (2000). Helicobacter pylori IgG antibody test established in the United States showed a substantially lower sensitivity for Japanese population. Am J Gastroenterol, 95, 1597-8.
32. Moayyedi P, Chalmers DM, Axon AT (1997). Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol, 32, 24-7.
33. Montecucco C, Rappuoli R (2001). Living dangerously: how Helicobacter pylori survives in the human stomach. Nature Rev, 2, 457-66.
34. Moshkowitz M, Konikoff FM, Peled Y, et al (1996). One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Aliment Pharmacol Ther, 10, 1015-9.
35. Munoz N (1994). Is Helicobacter pylori a cause of gastric cancer? An appraisal of the seroepidemiological evidence. Cancer Epidemiol Biomarkers Prev, 3, 445-451.
36. Murray LJ, McCrum EE, Evans AE, Bamford KB (1997). Epidemiology of Helicobacter pylori infection among 4742 randomly selected subjects from Northern Ireland. Int J Epidemiol, 26, 880-7.
37. Namekata T, Miki K, Kimmey M, et al (2000). Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle. Am J Epidemiol, 151, 820-30.
38. Ouyang Y, Virasch N, Hao P, et al (2000). Suppression of human IL-1β, IL-2, IFN-γ, and TNF-α production by cigarette smoke extracts. J Allergy Clin Immunol, 106, 280-7.
39. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A (2001). Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther, 15, 1023-9.
40. Tsugane S, Tei Y, Takahashi T, et al (1994). Salty food intake and risk of Helicobacter pylori infection. Jpn J Cancer Res, 85, 474-8.
41. Woodward M, Morrison C, McColl K (2000). An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol, 53, 175-82.
42. Xia HH, Talley NJ (1997). Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implication. Am J Gastroenterol, 92, 1780-7.
43. Yea SS, Yang YI, Jang WH, et al (2001). Association between TNFalpha promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol, 54, 703-6